/

Sociétés

Ba

Non vérifié

Bayer

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

176 communiqués de presse

Voir tous les communiqués de presse

01/10/2026

Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle

Source

Émetteur

1.00

0

29/09/2026

MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option

Source

Émetteur

1.00

0

28/09/2026

Industrie

Oncologie

Hygiène alimentaire

Santé

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer

Source

Émetteur

1.00

0

17/09/2026

Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs

Source

Émetteur

1.00

0

17/09/2026

Biotechnologie

Hygiène alimentaire

Santé Publique

Santé

Industrie pharmaceutique

Science

Médecine - Divers

Industrie

Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes

Source

Émetteur

1.00

0

10/09/2026

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

Source

Émetteur

1.00

0

10/09/2026

Industrie

Oncologie

Santé

Hygiène alimentaire

Santé Publique

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

Source

Émetteur

1.00

0

09/09/2026

Marché du travail

Industrie

Énergies Renouvelables

Énergie

Agriculture

Matières premières

Bayer and Neste Close Commercial Agreement to Jointly Scale newgold® Winter Canola for Biofuels Production

Source

Émetteur

1.00

0

09/09/2026

Industrie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Cardiologie

Biotechnologie

BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION

Source

Émetteur

1.00

0

02/09/2026

Industrie

Technique

Agriculture

Matières premières

Science

Bayer Advances Combined Seed and Crop Protection Pipeline and Enters Phase of Blockbuster Launches

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0